Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK 4-component Group A Streptococcus vaccine (alum)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK's 4-component Group A Streptococcus vaccine (alum) is an investigational protein-based vaccine developed by GSK for the prevention of Group A Streptococcal (Strep A) infections. The vaccine is composed of four synthetic peptides derived from *Streptococcus pyogenes* antigens and is formulated with an aluminum hydroxide (alum) adjuvant to enhance the immune response. It is currently in Phase 1 clinical development, where it is being evaluated for safety, reactogenicity, and immunogenicity in healthy young adults. The vaccine aims to provide broad protection against various manifestations of Strep A, including pharyngitis and invasive disease, while potentially preventing severe post-streptococcal sequelae such as rheumatic fever and rheumatic heart disease.
- Other names
- GSK 4-component Strep A vaccine (alum)Strep A Alum vaccineGSK 4-component Group A Streptococcus vaccine with alum adjuvantGSK4-component Group A Streptococcus vaccine with alum adjuvantGSK-4-component Group A Streptococcus vaccine with alum adjuvant
02
Targets
SLO (Streptolysin O)GAC (Group A carbohydrate antigen)SpyCEP (Streptococcus pyogenes cell envelope protease)
Beyond the preview
Go deeper on GSK 4-component Group A Streptococcus vaccine (alum).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK 4-component Group A Streptococcus vaccine (alum).